HIF1A and neoplasm: Luo et al. have shown that the HIF-1α inhibitor PX-478 (S-2-amino-3-[4′-N,N,-bis(chloroethyl)amino] phenyl propionic acid N-oxide dihydrochloride) in combination with anti-PD-1 causes marked tumor growth inhibition and prolonged survival in animal models of NSCLC, which correlates with increased TILs and granzyme B secretion [105].